-
-
-
-
-
-
-
Jefferies on Savara (SVRA): 'We remain 90% confident in Molbreevi's US approval by Aug 22, 2026'
-
-
-
-
-
-
-
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
-
-
-
-
-
-
-
Here's the list of biotech stocks that have key data catalysts in 2025
15,694 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

